Recent executive actions have advanced federal cannabis policy, with the Justice Department and DEA issuing an April 2026 order that moved FDA-approved marijuana products and those under state medical licenses from Schedule I to Schedule III, effective late that month. This followed a December 2025 presidential directive to expedite the process consistent with the Controlled Substances Act. An administrative hearing on broader rescheduling of all marijuana to Schedule III is now scheduled to begin June 29, 2026, and must conclude by mid-July. These steps address long-standing calls for reclassification based on medical evidence while preserving controls on non-medical use, with trader assessments reflecting the timeline for any final rulemaking on full Schedule III placement.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว$762,420 ปริมาณ
Mar 31, 2026
June 30
2%
December 31
26%
$762,420 ปริมาณ
June 30
$338,654 ปริมาณ
2%
December 31
$158,884 ปริมาณ
26%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent executive actions have advanced federal cannabis policy, with the Justice Department and DEA issuing an April 2026 order that moved FDA-approved marijuana products and those under state medical licenses from Schedule I to Schedule III, effective late that month. This followed a December 2025 presidential directive to expedite the process consistent with the Controlled Substances Act. An administrative hearing on broader rescheduling of all marijuana to Schedule III is now scheduled to begin June 29, 2026, and must conclude by mid-July. These steps address long-standing calls for reclassification based on medical evidence while preserving controls on non-medical use, with trader assessments reflecting the timeline for any final rulemaking on full Schedule III placement.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ตลาดเปิดเมื่อ: Feb 7, 2026, 5:04 PM ET
ปริมาณการซื้อขาย
$762,420วันสิ้นสุด
Mar 31, 2026ตลาดเปิดเมื่อ
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent executive actions have advanced federal cannabis policy, with the Justice Department and DEA issuing an April 2026 order that moved FDA-approved marijuana products and those under state medical licenses from Schedule I to Schedule III, effective late that month. This followed a December 2025 presidential directive to expedite the process consistent with the Controlled Substances Act. An administrative hearing on broader rescheduling of all marijuana to Schedule III is now scheduled to begin June 29, 2026, and must conclude by mid-July. These steps address long-standing calls for reclassification based on medical evidence while preserving controls on non-medical use, with trader assessments reflecting the timeline for any final rulemaking on full Schedule III placement.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ปริมาณการซื้อขาย
$762,420วันสิ้นสุด
Mar 31, 2026ตลาดเปิดเมื่อ
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...Recent executive actions have advanced federal cannabis policy, with the Justice Department and DEA issuing an April 2026 order that moved FDA-approved marijuana products and those under state medical licenses from Schedule I to Schedule III, effective late that month. This followed a December 2025 presidential directive to expedite the process consistent with the Controlled Substances Act. An administrative hearing on broader rescheduling of all marijuana to Schedule III is now scheduled to begin June 29, 2026, and must conclude by mid-July. These steps address long-standing calls for reclassification based on medical evidence while preserving controls on non-medical use, with trader assessments reflecting the timeline for any final rulemaking on full Schedule III placement.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย